Zacks: Analysts Expect Mylan (MYL) Will Announce Quarterly Sales of $3.28 Billion
Equities research analysts forecast that Mylan (NASDAQ:MYL) will post $3.28 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Mylan’s earnings. The highest sales estimate is $3.38 billion and the lowest is $3.19 billion. Mylan posted sales of $3.27 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 0.3%. The company is scheduled to issue its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that Mylan will report full-year sales of $3.28 billion for the current year, with estimates ranging from $11.86 billion to $12.05 billion. For the next year, analysts expect that the company will post sales of $12.65 billion per share, with estimates ranging from $12.28 billion to $13.18 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Mylan.
Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. During the same period in the previous year, the firm earned $1.38 EPS. The firm’s quarterly revenue was down 2.3% on a year-over-year basis.
A number of hedge funds and other institutional investors have recently made changes to their positions in MYL. Sei Investments Co. lifted its stake in Mylan by 24.2% during the 2nd quarter. Sei Investments Co. now owns 17,233 shares of the company’s stock valued at $669,000 after acquiring an additional 3,363 shares during the period. Global X Management Co. LLC lifted its stake in Mylan by 59.2% during the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock valued at $186,000 after acquiring an additional 1,786 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in Mylan by 2.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,602,389 shares of the company’s stock valued at $62,205,000 after acquiring an additional 33,510 shares during the period. Advisors Asset Management Inc. lifted its stake in Mylan by 5.7% during the 2nd quarter. Advisors Asset Management Inc. now owns 73,170 shares of the company’s stock valued at $2,840,000 after acquiring an additional 3,965 shares during the period. Finally, Legal & General Group Plc lifted its stake in Mylan by 12.8% during the 2nd quarter. Legal & General Group Plc now owns 2,437,073 shares of the company’s stock valued at $94,604,000 after acquiring an additional 277,404 shares during the period. Institutional investors and hedge funds own 75.04% of the company’s stock.
Mylan (NASDAQ:MYL) opened at $40.52 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. Mylan has a 12-month low of $29.39 and a 12-month high of $45.87. The stock has a market cap of $21,462.81, a P/E ratio of 8.51, a PEG ratio of 2.19 and a beta of 1.38.
TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/17/zacks-analysts-expect-mylan-myl-will-announce-quarterly-sales-of-3-28-billion.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.